Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plamotamab + tafasitamab + lenalidomide versus tafasitamab + lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
2021-003658-22Phase 2Terminated
- Sponsor
- Xencor
- Start
- Jul 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Plamotamab + tafasitamab + lenalidomide with Tafasitamab + lenalidomide (2 arms). Primary endpoints: Incidence of cytokine release syndrome and Treatment-emergent adverse events. Started Jul 2022; status: terminated.
02
Drugs
Plamotamabtafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2021-003658-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003658-22.